KBY Biotech Indexv0.0.34
Search
← Pipeline|Rimalucimab

Rimalucimab

Phase 2/3
TEV-8712
By Teva Pharma
Source: Trial-derived·Trials: 2
Modality
Multispecific
MOA
CD47i
Target
KIF18A
Pathway
PD-1/PD-L1
CholangiocarcinomaSCD
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
~Oct 2019
→ ~Jan 2021
Phase 2
Apr 2021
→ Mar 2031
Phase 2Current
NCT07876905
952 pts·Cholangiocarcinoma
2025-05→2031-03·Active
NCT07662885
175 pts·SCD
2021-04→2026-01·Active
1,127 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-272mo agoPh3 Readout· SCD
2031-03-185.0y awayPh3 Readout· Cholangiocarcinoma
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2/3
Active
P2/3
Active
Catalysts
Ph3 Readout
2026-01-27 · 2mo ago
SCD
Ph3 Readout
2031-03-18 · 5.0y away
Cholangiocarcinoma
Active|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT07876905Phase 2/3CholangiocarcinomaActive952BodyWt
NCT07662885Phase 2/3SCDActive175OS
Competitors (10)
DrugCompanyPhaseTargetMOA
NiranesiranJohnson & JohnsonPhase 2KIF18AEGFRi
NirarelsinJohnson & JohnsonPhase 2PRMT5CD47i
CevizanubrutinibJohnson & JohnsonPreclinicalFcRnCD47i
CeviglumideRocheNDA/BLAB7-H3CD47i
NVS-1475NovartisPhase 2MeninCD47i
AZN-6294AstraZenecaPhase 2/3APOC3CD47i
ZenonesiranGSKPreclinicalDLL3CD47i
AMG-7379AmgenPreclinicalDLL3CD47i
RiluinavolisibModernaNDA/BLAKIF18APLK4i
BGN-3859BeiGeneApprovedPSMACD47i